Per­spec­tive’s ear­ly da­ta on lead-based ra­dio­phar­ma as­set sug­gest low­er dose did bet­ter

In ear­ly-stage tri­als called dose es­ca­la­tion stud­ies, drug de­vel­op­ers usu­al­ly want to test pro­gres­sive­ly high­er dos­es of their ther­a­pies.

Not Per­spec­tive Ther­a­peu­tics. The ra­dio­phar­ma biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER